CGS-authored
Even among the hyperactive overachieving techies in his cohort, Martin Varsavsky stands out. He’s built more successful businesses–six–than all but the most prolific serial entrepreneurs. He’s also fathered more children–six as well–than all but the most prolific dads. Yet at 56 Varsavsky, one of the most recognizable figures in Europe’s tech scene, is going for something of a “lucky seven.” Twice.
After moving to the United States from Spain two years ago, he set to work launching another company. And his wife, Nina, is expecting another child in January, their third together. “We call him Seven for now,” Varsavsky quips. The two sevens are inextricably linked. His new startup, Prelude Fertility, whose story is being told here for the first time, has a bold plan to turn the infertility industry on its head. Varsavsky isn’t just Prelude’s founder–Seven, his upcoming child, will be the first “Prelude baby.”
Armed with $200 million, Prelude plans to take the technology of infertility–in vitro fertilization and egg freezing–and aggressively expand it into fertility, hoping to usher in a world where women’s decisions about...